Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S1-221 Single Ascending Dose, Food Effect, and Crossover Study in Healthy Participants
NCT07146945Phase 1Completed
- Sponsor
- Delphian Therapeutics
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of S1-221 (6 arms), sponsored by Delphian Therapeutics. Primary endpoints: Treatment-emergent Adverse Events up to 49 days and Treatment-emergent abuse-related Adverse Events up to 49 days. Started Aug 2025; status: completed.
02
Drugs
S1-221
Beyond the preview
Go deeper on NCT07146945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07146945.